References
- Gifford RW Jr. Resistant hypertension. Introduction and definitions. Hypertension 1988;11(3 Pt 2):II65-6.
- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19. https://doi.org/10.1161/HYPERTENSIONAHA.108.189141
- Lee RE, Seligmann AW, Clark MA, Borhani NO, Queenan JT, O'Brien ME. Therapeutically refractory hypertension: causative factors, and medical management with chlorothiazide and other agents. Ann Intern Med 1958;49:1129-37. https://doi.org/10.7326/0003-4819-49-5-1129
- Leslie CH. A new antihypertensive drug (mebutamate) in the treatment of refractory hypertension in geriatric patients: preliminary report. J Am Geriatr Soc 1962;10:85-9. https://doi.org/10.1111/j.1532-5415.1962.tb00246.x
- Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012;14:7-12. https://doi.org/10.1111/j.1751-7176.2011.00556.x
- Gifford RW, Jr, Tarazi RC. Resistant hypertension: diagnosis and management. Ann Intern Med 1978;88:661-5. https://doi.org/10.7326/0003-4819-88-5-661
- Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014;63:451-8. https://doi.org/10.1161/HYPERTENSIONAHA.113.02026
- Modolo R, de Faria AP, Sabbatini AR, Barbaro NR, Ritter AM, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens 2015;9:397-402. https://doi.org/10.1016/j.jash.2015.03.005
- Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension 2015;66:126-33. https://doi.org/10.1161/HYPERTENSIONAHA.115.05449
- Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013;88:1099-107. https://doi.org/10.1016/j.mayocp.2013.06.017
- de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898-902. https://doi.org/10.1161/HYPERTENSIONAHA.110.168948
- Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012;27:386-91. https://doi.org/10.1097/HCO.0b013e328353ad6e
- Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-74. https://doi.org/10.1097/HJH.0b013e32835e2286
- Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013;62:691-7. https://doi.org/10.1161/HYPERTENSIONAHA.113.01448
- Grigoryan L, Pavlik VN, Hyman DJ. Patterns of nonadherence to antihypertensive therapy in primary care. J Clin Hypertens (Greenwich) 2013;15:107-11. https://doi.org/10.1111/jch.12030
- Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58. https://doi.org/10.1161/CIRCULATIONAHA.111.030189
- Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-80. https://doi.org/10.1161/HYPERTENSIONAHA.111.170308
- Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatmentresistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014;8:405-13. https://doi.org/10.1016/j.jash.2014.03.003
- Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005;25:135-43. https://doi.org/10.1159/000086678
- Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and endstage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014;64:1012-21. https://doi.org/10.1161/HYPERTENSIONAHA.114.03850
- Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 2014;127:71-81.e1. https://doi.org/10.1016/j.amjmed.2013.07.038
- Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-42. https://doi.org/10.1161/CIRCULATIONAHA.111.068064
- Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013;34:1204-14. https://doi.org/10.1093/eurheartj/ehs368
- Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39:982-8. https://doi.org/10.1161/01.HYP.0000016176.16042.2F
- Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6. https://doi.org/10.1161/01.HYP.0000040261.30455.B6
- Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-26. https://doi.org/10.1097/00004872-200411000-00026
- Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64. https://doi.org/10.1001/archinte.168.11.1159
- Sartori M, Calo LA, Mascagna V, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19:373-9; discussion 380. https://doi.org/10.1016/j.amjhyper.2005.06.031
- Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475-81. https://doi.org/10.1161/HYPERTENSIONAHA.109.131235
- Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005;85:679-715. https://doi.org/10.1152/physrev.00056.2003
Cited by
- Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag? vol.20, pp.3, 2018, https://doi.org/10.1007/s11906-018-0825-7
- Resistant hypertension: a therapeutic challenge vol.20, pp.1, 2016, https://doi.org/10.1111/jch.13144
- Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus vol.20, pp.5, 2016, https://doi.org/10.1111/jch.13293
- Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial vol.19, pp.1, 2018, https://doi.org/10.1186/s13063-017-2343-3
- Resistant and refractory hypertension: two sides of the same disease? vol.41, pp.2, 2016, https://doi.org/10.1590/2175-8239-jbn-2018-0108
- Effect of exercise and physical activity on blood pressure in adults with resistant hypertension: a protocol for a systematic review vol.25, pp.2, 2016, https://doi.org/10.1080/10833196.2020.1728986
- Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting vol.33, pp.4, 2020, https://doi.org/10.1093/ajh/hpz196
- Exercise: a therapeutic modality to treat blood pressure in resistant hypertension vol.25, pp.3, 2016, https://doi.org/10.1080/10833196.2020.1733781